Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PIPERACILLIN SODIUM, TAZOBACTAM (AS SODIUM SALT)
Teva Pharma B.V.
J01CR05
PIPERACILLIN SODIUM, TAZOBACTAM (AS SODIUM SALT)
4g/500 Milligram
Pdr for Soln for Infusion
Product subject to prescription which may not be renewed (A)
Combinations of penicillins, incl. beta-lactamase inhibitors
Authorised
2010-09-03
1 PACKAGE LEAFLET: INFORMATION FOR THE USER PIPERACILLIN/TAZOBACTAM TEVA 4 G/500 MG POWDER FOR SOLUTION FOR INFUSION piperacillin/ tazobactam READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Piperacillin/Tazobactam Teva is and what it is used for 2. What you need to know before you use Piperacillin/Tazobactam Teva 3. How to use Piperacillin/Tazobactam Teva 4. Possible side effects 5. How to store Piperacillin/Tazobactam Teva 6. Contents of the pack and other information 1. WHAT PIPERACILLIN/TAZOBACTAM TEVA IS AND WHAT IT IS USED FOR Piperacillin belongs to the group of medicines known as “broad-spectrum penicillin antibiotics”. It can kill many kinds of bacteria. Tazobactam can prevent some resistant bacteria from surviving the effects of piperacillin. This means that when piperacillin and tazobactam are given together, more types of bacteria are killed. Piperacillin/Tazobactam Teva is used in adults and adolescents to treat bacterial infections, such as those affecting the lower respiratory tract (lungs), urinary tract (kidneys and bladder), abdomen, skin or blood. Piperacillin/Tazobactam Teva may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections). Piperacillin/Tazobactam Teva is used in children aged 2-12 to treat infections of the abdomen such as appendicitis, peritonitis (infection of the fluid and lining of the abdominal organs), and gallbladder (biliary) infections. Piperacillin/Tazobactam Teva may be used to treat bacterial infections in patients with low white blood cell counts (reduced resistance to infections). In certain serious infections, your docto Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Piperacillin/Tazobactam Teva 4 g/500 mg Powder for Solution for Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains piperacillin (as sodium salt) equivalent to 4 g and tazobactam (as sodium salt) equivalent to 0.5 g. Each vial of Piperacillin/Tazobactam Teva 4 g/500 mg contains 9.4 mmol (216 mg) of sodium. This medicinal product contains no excipients. 3 PHARMACEUTICAL FORM Powder for solution for infusion. White or off-white powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Piperacillin/Tazobactam Teva is indicated for the treatment of the following infections in adults and children over 2 years of age (see sections 4.2 and 5.1): Adults and adolescents Severe pneumonia including hospital-acquired and ventilator-associated pneumonia Complicated urinary tract infections (including pyelonephritis) Complicated intra-abdominal infections Complicated skin and soft tissue infections (including diabetic foot infections) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Piperacillin/Tazobactam Teva may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection. Children 2 to 12 years of age Complicated intra-abdominal infections Piperacillin/Tazobactam Teva may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document